Pasithea Therapeutics Enterprise Value Over Time
| KTTA Stock | USD 2.56 0.24 8.57% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pasithea Therapeutics Performance and Pasithea Therapeutics Correlation. Pasithea |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.79) | Revenue Per Share | Quarterly Revenue Growth 14.981 | Return On Assets | Return On Equity |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Enterprise Value Analysis
Compare Pasithea Therapeutics and related stocks such as Nutriband Warrant, Zivo Bioscience, and MediciNova Enterprise Value Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRBW | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 179.4 M | 179.4 M | 87.3 M | 105.6 M | 25 M | 29.1 M | 20.5 M | 23.6 M | 22.4 M |
| MNOV | 60.1 M | 10.1 M | 24.3 M | 37.6 M | 80.2 M | 85 M | 175.8 M | 199.3 M | 300.9 M | 227.5 M | 173.8 M | 58.9 M | 82.2 M | 82.2 M | 74 M | 82.8 M |
| VRAX | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.9 M) | (2.2 M) | (2.3 M) |
| REVB | 88.8 M | 88.8 M | 88.8 M | 88.8 M | 88.8 M | 88.8 M | 88.8 M | 88.8 M | 88.8 M | 88.8 M | 86.9 M | 99.4 M | (1.7 M) | (1.7 M) | (1.9 M) | (1.8 M) |
| KPRX | 140.5 M | 140.5 M | 140.5 M | 140.5 M | 140.5 M | 140.5 M | 140.5 M | 140.5 M | 140.5 M | 202.9 M | 202.9 M | 123.4 M | 16.7 M | 180.8 K | 208 K | 197.6 K |
| KZR | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 2.3 B | 756.7 M | 756.7 M | 670.5 M | 670.5 M | 670.5 M | 670.5 M | 771.1 M | 732.5 M |
| KRON | 760.7 M | 760.7 M | 760.7 M | 760.7 M | 760.7 M | 760.7 M | 760.7 M | 760.7 M | 760.7 M | 1.4 B | 1.2 B | 438.4 M | 46.2 M | 46.2 M | 53.1 M | 50.4 M |
| QNRX | 544.4 K | 544.4 K | 544.4 K | 544.4 K | 544.4 K | 544.4 K | 12.5 M | 35.2 M | 8.8 M | (210.7 K) | 4 M | 4 M | 4 M | 2 M | 2.3 M | 2.2 M |
| RNXT | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 63.9 M | 28 M | 14.8 M | 22.4 M | 25.8 M | 44.5 M |
| ABVC | 2.5 M | 2.2 M | 2 M | 660.5 K | 125.1 M | 80.9 M | 80.9 M | 80.9 M | 80.9 M | 80.9 M | 82.2 M | 82.2 M | 82.2 M | 82.2 M | 94.5 M | 89.8 M |
| INDP | 18 M | 18 M | 18 M | 18 M | 18 M | 18 M | 195.9 M | 195.9 M | 195.9 M | 5.1 M | 5.1 M | (15.6 M) | 2.4 M | 2.4 M | 2.8 M | 2.7 M |
| FBRX | 236.3 M | 236.3 M | 236.3 M | 236.3 M | 236.3 M | 236.3 M | 261.7 M | 124.6 M | 18.7 M | 18.7 M | 209.2 M | 14 M | 14 M | 14 M | 16.1 M | 15.3 M |
Pasithea Therapeutics and related stocks such as Nutriband Warrant, Zivo Bioscience, and MediciNova Enterprise Value description
Enterprise Value (or EV) is usually referred to as Pasithea Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Pasithea Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of Pasithea Therapeutics value than its market capitalization because it takes into account all of Pasithea Therapeutics Corp existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.My Equities
My Current Equities and Potential Positions
| Pasithea Therapeutics Corp | KTTA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.56
Check out Pasithea Therapeutics Performance and Pasithea Therapeutics Correlation. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Pasithea Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.